BioWorld - Saturday, May 16, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: Tracking hantavirus across the globeBreaking News: Tracking hantavirus across the globe

BioWorld Science
BioWorld Science RSS Feed RSS

Cancer

Shanghai Meiyue Biotech Development patents new VAV1 degradation inducers

April 1, 2026
Shanghai Meiyue Biotech Development Co. Ltd. has disclosed new molecular glue degraders comprising an E3 ubiquitin-protein ligase binding agents coupled to proto-oncogene Vav (VAV1) acting as VAV1 degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, renal, metabolic, inflammatory and neurological disorders.
Read More
Liver tumor treatment conceptual illustration
Cancer

Potential first-in-class RNF4 PROTAC for HCC disclosed

April 1, 2026
No Comments
Ring finger protein 4 (RNF4) is a SUMO-targeted ubiquitin ligase that modulates proteins involved in cancer progression. Researchers from Chongqing Medical University and collaborators reported the development and preclinical characterization of [I], the first RNF4-targeting PROTAC degrader for the treatment of hepatocellular carcinoma (HCC).
Read More
Illustration of cancer inside colon
Cancer

Covalent ULK1 inhibitor shows potent antitumor activity in CRC

April 1, 2026
No Comments
Researchers from Sichuan University reported the discovery and preclinical characterization of a new series of covalent ULK1 inhibitors. ULK1 is frequently overexpressed in colorectal cancer (CRC) and is therefore being investigated as a therapeutic target to disrupt autophagy-dependent tumor survival and growth.
Read More
Chromatin compaction
Drug design, drug delivery & technologies

Tippingpoint raises seed financing to target epigenetic protein interfaces

April 1, 2026
No Comments
Tippingpoint Biosciences Inc. has closed an oversubscribed $4.5 million seed financing. The company, spun out of a lab at University of California, San Francisco (UCSF), is advancing its novel drug discovery platform designed to identify first-in-class drugs to treat diseases related to dysfunctional DNA packaging (chromatin).
Read More